Treatment Resistant Depression Market Report and Forecast 2024-2032
Treatment Resistant Depression Market Report and Forecast 2024-2032
Treatment Resistant Depression Market Outlook
The treatment resistant depression market size was valued at USD 2.8 billion in 2023, driven growing emphasis on personalized or precision medicine across the major markets. The market size is anticipated to grow at a CAGR of 6.7% during the forecast period of 2024-2032, with the values likely to rise to USD 4.9 billion by 2032.
Treatment Resistant Depression: Introduction
Treatment-resistant depression (TRD) refers to major depressive disorder (MDD) that does not respond adequately to at least two different antidepressant treatments given at adequate doses and durations. TRD poses significant challenges in mental health care, leading to prolonged suffering and increased risk of suicide. Management strategies may include medication adjustments, adding adjunctive therapies, psychotherapy, and considering alternative treatments like electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), or ketamine infusions to alleviate symptoms and improve quality of life.
Key Trends in the Treatment Resistant Depression Market
There is a growing trend towards personalized or precision medicine in treating TRD, involving genetic testing and biomarker analysis to tailor treatment strategies to individual patient profiles. This approach aims to improve treatment efficacy and reduce trial-and-error prescribing.
Neuromodulation techniques such as Transcranial Magnetic Stimulation (TMS) and Electroconvulsive Therapy (ECT) are gaining traction as effective treatments for TRD. The development and approval of newer neuromodulation technologies, including Deep Brain Stimulation (DBS) and Vagus Nerve Stimulation (VNS), reflect this trend.
The market is seeing an influx of novel pharmacotherapies targeting mechanisms of action different from traditional antidepressants. Drugs like esketamine, approved for TRD, represent this shift towards innovative treatment modalities offering rapid relief of symptoms.
Digital health technologies, including telepsychiatry, mobile apps for mental health management, and wearable devices for monitoring physiological markers, are becoming integral to managing TRD. These technologies support remote monitoring, patient engagement, and personalized care plans.
There is a notable shift towards comprehensive, multidisciplinary care models that address the multifaceted nature of TRD. These models incorporate pharmacological treatments, psychotherapy, lifestyle modifications, and social support to address the broad spectrum of needs among individuals with TRD.
Collaborative research efforts and partnerships between academic institutions, pharmaceutical companies, and mental health organizations are vital in advancing the understanding and treatment of TRD. These collaborations are crucial for driving innovation in therapeutic approaches and developing new treatment paradigms.
Treatment Resistant Depression Market Segmentation
Market Breakup by Drug Class
- Selective Serotonin Reuptake Inhibitors (SSRIS)
- Monoamine Oxidase Inhibitors
- Tricyclic Antidepressant
- Psychedelics
- Others
- Oral
- Parenteral
- Others
- Hospitals
- Specialty Clinics
- Others
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
In North America, the market for treatment-resistant depression (TRD) is advanced, with a strong emphasis on developing and adopting innovative therapies. There's a significant focus on personalized medicine approaches, including genetic testing to tailor antidepressant treatments. The region has seen the approval and increased use of novel treatment options such as ketamine and esketamine nasal spray, alongside non-pharmacological interventions like transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT). Awareness and acceptance of mental health issues are high, driving demand for effective TRD treatments.
Europe's TRD market is characterized by comprehensive healthcare systems that support access to a wide range of treatments, including pharmacological interventions, psychotherapy, and novel therapies. The region shows a strong commitment to mental health research, with ongoing trials exploring new treatment modalities. Regulatory bodies in Europe have been proactive in evaluating and approving new therapies, with a growing interest in digital health solutions and interventions to support individuals with TRD.
In Japan, the market for TRD treatment reflects the country's high standard of healthcare and openness to innovative treatment techniques. Japan has a keen interest in integrating technology into healthcare, leading to the exploration of digital therapeutics and mobile applications for managing depression. The adoption of new pharmacological treatments is carefully regulated, with a growing interest in evidence-based alternative treatments. Public and private sector collaboration is evident in efforts to address the stigma associated with mental health and improve access to care for individuals with TRD.
Treatment Resistant Depression Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
- Pfizer Inc
- Mylan N.V.
- Hikma Pharmaceuticals plc
- AbbVie Inc.
- Melinta Therapeutics, Inc
- Bristol Myers Squibb Company
- GSK Plc.
- Bayer AG
- Perrigo Company plc
- Johnson & Johnson Services, Inc
- Amneal Pharmaceuticals LLC. (U.S.)
- Teva Pharmaceutical Industries Ltd
- Endo Pharmaceuticals plc
- Currax Pharmaceuticals LLC
- Eli Lilly and Company
*Please Note:* The report will take 7 business days to complete, after order confirmation.
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Treatment Resistant Depression Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Treatment Resistant Depression Epidemiology Analysis – 7MM
- 5.1 7MM Epidemiology Scenario Overview (2017-2032)
- 5.2 United States Treatment Resistant Depression Epidemiology Forecast (2017-2032)
- 5.3 EU-4 and United Kingdom Treatment Resistant Depression Epidemiology Forecast (2017-2032)
- 5.3.1 Germany Treatment Resistant Depression Epidemiology Forecast (2017-2032)
- 5.3.2 France Treatment Resistant Depression Epidemiology Forecast (2017-2032)
- 5.3.3 Italy Treatment Resistant Depression Epidemiology Forecast (2017-2032)
- 5.3.4 Spain Treatment Resistant Depression Epidemiology Forecast (2017-2032)
- 5.3.5 United Kingdom Treatment Resistant Depression Epidemiology Forecast (2017-2032)
- 5.4 Japan Treatment Resistant Depression Epidemiology Forecast (2017-2032)
- 6 Treatment Resistant Depression Market Overview – 7MM
- 6.1 Treatment Resistant Depression Market Historical Value (2017-2023)
- 6.2 Treatment Resistant Depression Market Forecast Value (2024-2032)
- 7 Treatment Resistant Depression Market Landscape – 7MM
- 7.1 Treatment Resistant Depression: Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Treatment Resistant Depression Product Landscape
- 7.2.1 Analysis by Drug Class
- 7.2.2 Analysis by Route of Administration
- 8 Treatment Resistant Depression Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Treatment Resistant Depression Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Treatment Resistant Depression Market Segmentation – 7MM
- 11.1 Treatment Resistant Depression Market by Drug Class
- 11.1.1 Market Overview
- 11.1.2 Selective Serotonin Reuptake Inhibitors (SSRIS)
- 11.1.3 Monoamine Oxidase Inhibitors
- 11.1.4 Tricyclic Antidepressant
- 11.1.5 Psychedelics
- 11.1.6 Others
- 11.2 Treatment Resistant Depression Market by Route of Administration
- 11.2.1 Market Overview
- 11.2.2 Oral
- 11.2.3 Parenteral
- 11.2.4 Others
- 11.3 Treatment Resistant Depression Market by End User
- 11.3.1 Market Overview
- 11.3.2 Hospitals
- 11.3.3 Specialty Clinics
- 11.3.4 Others
- 11.4 Treatment Resistant Depression Market by Distribution Channel
- 11.4.1 Hospital Pharmacy
- 11.4.2 Retail Pharmacy
- 11.4.3 Online Pharmacy
- 11.5 Treatment Resistant Depression Market by Region
- 11.5.1 Market Overview
- 11.5.2 United States
- 11.5.3 EU-4 and the United Kingdom
- 11.5.3.1 Germany
- 11.5.3.2 France
- 11.5.3.3 Italy
- 11.5.3.4 Spain
- 11.5.3.5 United Kingdom
- 11.5.4 Japan
- 12 United States Treatment Resistant Depression Market
- 12.1 Treatment Resistant Depression Market Historical Value (2017-2023)
- 12.2 Treatment Resistant Depression Market Forecast Value (2024-2032)
- 12.3 Treatment Resistant Depression Market by Drug Class
- 12.4 Treatment Resistant Depression Market by Route of Administration
- 13 EU-4 and United Kingdom Treatment Resistant Depression Market
- 13.1 Treatment Resistant Depression Market Historical Value (2017-2023)
- 13.2 Treatment Resistant Depression Market Forecast Value (2024-2032)
- 13.3 Germany Treatment Resistant Depression Market Overview
- 13.3.1 Treatment Resistant Depression Market by Drug Class
- 13.3.2 Treatment Resistant Depression Market by Route of Administration
- 13.4 France Treatment Resistant Depression Market Overview
- 13.4.1 Treatment Resistant Depression Market by Drug Class
- 13.4.2 Treatment Resistant Depression Market by Route of Administration
- 13.5 Italy Treatment Resistant Depression Market Overview
- 13.5.1 Treatment Resistant Depression Market by Drug Class
- 13.5.2 Treatment Resistant Depression Market by Route of Administration
- 13.6 Spain Treatment Resistant Depression Market Overview
- 13.6.1 Treatment Resistant Depression Market by Drug Class
- 13.6.2 Treatment Resistant Depression Market by Route of Administration
- 13.7 United Kingdom Treatment Resistant Depression Market Overview
- 13.7.1 Treatment Resistant Depression Market by Drug Class
- 13.7.2 Treatment Resistant Depression Market by Route of Administration
- 14 Japan Treatment Resistant Depression Market
- 14.1 Treatment Resistant Depression Market Historical Value (2017-2023)
- 14.2 Treatment Resistant Depression Market Forecast Value (2024-2032)
- 14.3 Treatment Resistant Depression Market by Drug Class
- 14.4 Treatment Resistant Depression Market by Route of Administration
- 15 Regulatory Framework
- 15.1 Regulatory Overview
- 15.1.1 US FDA
- 15.1.2 EU EMA
- 15.1.3 JAPAN PMDA
- 16 Patent Analysis
- 16.1 Analysis by Type of Patent
- 16.2 Analysis by Publication year
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Patent Age
- 16.5 Analysis by CPC Analysis
- 16.6 Analysis by Patent Valuation
- 16.7 Analysis by Key Players
- 17 Grants Analysis
- 17.1 Analysis by year
- 17.2 Analysis by Amount Awarded
- 17.3 Analysis by Issuing Authority
- 17.4 Analysis by Grant Application
- 17.5 Analysis by Funding Institute
- 17.6 Analysis by NIH Departments
- 17.7 Analysis by Recipient Organization
- 18 Clinical Trials Analysis
- 18.1 Analysis by Trial Registration Year
- 18.2 Analysis by Trial Status
- 18.3 Analysis by Trial Phase
- 18.4 Analysis by Therapeutic Area
- 18.5 Analysis by Geography
- 19 Funding and Investment Analysis
- 19.1 Analysis by Funding Instances
- 19.2 Analysis by Type of Funding
- 19.3 Analysis by Funding Amount
- 19.4 Analysis by Leading Players
- 19.5 Analysis by Leading Investors
- 19.6 Analysis by Geography
- 20 Partnerships and Collaborations Analysis
- 20.1 Analysis by Partnership Instances
- 20.2 Analysis by Type of Partnership
- 20.3 Analysis by Leading Players
- 20.4 Analysis by Geography
- 21 Supplier Landscape
- 21.1 Pfizer Inc
- 21.1.1 Financial Analysis
- 21.1.2 Product Portfolio
- 21.1.3 Demographic Reach and Achievements
- 21.1.4 Mergers and Acquisitions
- 21.1.5 Certifications
- 21.2 Mylan N.V.
- 21.2.1 Financial Analysis
- 21.2.2 Product Portfolio
- 21.2.3 Demographic Reach and Achievements
- 21.2.4 Mergers and Acquisitions
- 21.2.5 Certifications
- 21.3 Hikma Pharmaceuticals plc
- 21.3.1 Financial Analysis
- 21.3.2 Product Portfolio
- 21.3.3 Demographic Reach and Achievements
- 21.3.4 Mergers and Acquisitions
- 21.3.5 Certifications
- 21.4 AbbVie Inc.
- 21.4.1 Financial Analysis
- 21.4.2 Product Portfolio
- 21.4.3 Demographic Reach and Achievements
- 21.4.4 Mergers and Acquisitions
- 21.4.5 Certifications
- 21.5 Melinta Therapeutics, Inc
- 21.5.1 Financial Analysis
- 21.5.2 Product Portfolio
- 21.5.3 Demographic Reach and Achievements
- 21.5.4 Mergers and Acquisitions
- 21.5.5 Certifications
- 21.6 Bristol Myers Squibb Company
- 21.6.1 Financial Analysis
- 21.6.2 Product Portfolio
- 21.6.3 Demographic Reach and Achievements
- 21.6.4 Mergers and Acquisitions
- 21.6.5 Certifications
- 21.7 GSK Plc.
- 21.7.1 Financial Analysis
- 21.7.2 Product Portfolio
- 21.7.3 Demographic Reach and Achievements
- 21.7.4 Mergers and Acquisitions
- 21.7.5 Certifications
- 21.8 Bayer AG
- 21.8.1 Financial Analysis
- 21.8.2 Product Portfolio
- 21.8.3 Demographic Reach and Achievements
- 21.8.4 Mergers and Acquisitions
- 21.8.5 Certifications
- 21.9 Perrigo Company plc
- 21.9.1 Financial Analysis
- 21.9.2 Product Portfolio
- 21.9.3 Demographic Reach and Achievements
- 21.9.4 Mergers and Acquisitions
- 21.9.5 Certifications
- 21.10 Johnson & Johnson Services, Inc
- 21.10.1 Financial Analysis
- 21.10.2 Product Portfolio
- 21.10.3 Demographic Reach and Achievements
- 21.10.4 Mergers and Acquisitions
- 21.10.5 Certifications
- 21.11 Amneal Pharmaceuticals LLC. (U.S.)
- 21.11.1 Financial Analysis
- 21.11.2 Product Portfolio
- 21.11.3 Demographic Reach and Achievements
- 21.11.4 Mergers and Acquisitions
- 21.11.5 Certifications
- 21.12 Teva Pharmaceutical Industries Ltd
- 21.12.1 Financial Analysis
- 21.12.2 Product Portfolio
- 21.12.3 Demographic Reach and Achievements
- 21.12.4 Mergers and Acquisitions
- 21.12.5 Certifications
- 21.13 Endo Pharmaceuticals plc
- 21.13.1 Financial Analysis
- 21.13.2 Product Portfolio
- 21.13.3 Demographic Reach and Achievements
- 21.13.4 Mergers and Acquisitions
- 21.13.5 Certifications
- 21.14 Currax Pharmaceuticals LLC
- 21.14.1 Financial Analysis
- 21.14.2 Product Portfolio
- 21.14.3 Demographic Reach and Achievements
- 21.14.4 Mergers and Acquisitions
- 21.14.5 Certifications
- 21.15 Eli Lilly and Company
- 21.15.1 Financial Analysis
- 21.15.2 Product Portfolio
- 21.15.3 Demographic Reach and Achievements
- 21.15.4 Mergers and Acquisitions
- 21.15.5 Certifications
- 22 Treatment Resistant Depression Market- Distribution Model (Additional Insight)
- 22.1 Overview
- 22.2 Potential Distributors
- 22.3 Key Parameters for Distribution Partner Assessment
- 23 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 24 Company Competitiveness Analysis (Additional Insight)
- 24.1 Very Small Companies
- 24.2 Small Companies
- 24.3 Mid-Sized Companies
- 24.4 Large Companies
- 24.5 Very Large Companies
- 25 Payment Methods (Additional Insight)
- 25.1 Government Funded
- 25.2 Private Insurance
- 25.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook